Company Overview of Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. develops biofluid based molecular diagnostic tests for use in personalized medicine. Its exosome technology makes use of exosomes to achieve high sensitivity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The company focuses on commercializing high sensitivity/specificity RNA in vitro diagnostic assays for use in disease recurrence monitoring and as companion diagnostics for use with targeted molecular therapies. Exosome Diagnostics, Inc. has a strategic collaboration with QIAGEN. The company was founded in 2008 and is headquartered in New York, New York with facilities in New York; St. Paul, Minnesota; and Munich, ...
Columbia University Medical Center
Lasker Biomedical Research Building
New York, NY 10032
Founded in 2008
Key Executives for Exosome Diagnostics, Inc.
Chief Executive Officer and Director
Vice President of Business Development
Director of European Operations
Compensation as of Fiscal Year 2014.
Exosome Diagnostics, Inc. Key Developments
Exosome Diagnostics Appoints Vincent J. O'Neill as Chief Medical Officer
Jun 3 14
Exosome Diagnostics announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalised medicine, most recently as global head personalised of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalised medicine strategy built the internal infrastructure and designed best practice protocols. He also created alliances and agreements with diagnostic testing laboratories and in vitro diagnostic companies. Prior to working at Sanofi, Dr. O'Neill managed the clinical development programs of several oncology therapeutic candidates, including biomarker development, at both Genentech and GlaxoSmithkline. He was instrumental in the expanded approval of products such as Avastin(R) and Tarceva(R) at Genentech. At GlaxoSmithkline, he managed the signal transduction discovery unit from which the first Investigative New Drug (IND) application and clinical trial, including patient selection strategy, of an MEK inhibitor (Mekinist(R)) was conducted.
Exosome Diagnostics Appoints William J. Kelly as Chief Financial Officer
May 28 14
Exosome Diagnostics announced that William J. Kelly has been appointed as its chief financial officer, effective May 27, 2014. For the past six years, Mr. Kelly worked at RepliGen Corporation, where he was the company's principal financial officer for more than five of those years, serving as either chief accounting officer or chief financial officer since 2008. Mr. Kelly is a Certified Public Accountant. While working at Deloitte & Touche LLP in their Boston and Dublin, Ireland, audit practices, he helped lead clients through numerous initial and subsequent public offerings and acquisition transactions.
Exosome Diagnostics, Inc. Presents at 2014 Leerink Swann Global Healthcare Conference, Feb-13-2014 11:35 AM
Feb 4 14
Exosome Diagnostics, Inc. Presents at 2014 Leerink Swann Global Healthcare Conference, Feb-13-2014 11:35 AM. Venue: The Waldorf Astoria Hotel, New York, New York, United States. Speakers: James R. McCullough, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 3, 2014